Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer
Prospective, Multicenter Study Investigating Efficacy and Safety of Oral Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism in Korean Patients With Cancers
Sponsor: Korean Society of Hematology Thrombosis Working Party
Listed as NCT01989845, this PHASE4 trial focuses on Bleeding and Cancer-associated Thrombosis and remains completed. Sponsored by Korean Society of Hematology Thrombosis Working Party, it has been updated 7 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
Status: Active Not Recruiting → Completed
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE4
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Korean Society of Hematology Thrombosis Working Party
- Seoul National University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .